Literature DB >> 11123033

Clinical trials in systemic lupus erythematosus.

J P Buyon1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11123033     DOI： 10.1007/s11926-996-0062-y

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  14 in total

1.  Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes.

Authors:  M Koshy; D Berger; M K Crow
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.

Authors:  R F van Vollenhoven; L M Morabito; E G Engleman; J L McGuire
Journal:  J Rheumatol       Date:  1998-02       Impact factor: 4.666

3.  Response criteria for clinical trials in systemic lupus erythematosus.

Authors:  M H Liang; P R Fortin
Journal:  Lupus       Date:  1995-10       Impact factor: 2.911

4.  Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus.

Authors:  J R Carneiro; E I Sato
Journal:  J Rheumatol       Date:  1999-06       Impact factor: 4.666

5.  Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study.

Authors:  J Alvarez-Nemegyei; A Cobarrubias-Cobos; F Escalante-Triay; J Sosa-Muñoz; J M Miranda; L J Jara
Journal:  Lupus       Date:  1998       Impact factor: 2.911

6.  Recruitment strategies in superiority trials in SLE: lessons from the study of methotrexate in lupus erythematosus (SMILE).

Authors:  D Ferland; P R Fortin
Journal:  Lupus       Date:  1999       Impact factor: 2.911

7.  A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus.

Authors:  R F van Vollenhoven; J L Park; M C Genovese; J P West; J L McGuire
Journal:  Lupus       Date:  1999       Impact factor: 2.911

8.  Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production.

Authors:  A Desai-Mehta; L Lu; R Ramsey-Goldman; S K Datta
Journal:  J Clin Invest       Date:  1996-05-01       Impact factor: 14.808

9.  No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus.

Authors:  D Buskila; M Lorber; L Neumann; D Flusser; Y Shoenfeld
Journal:  J Rheumatol       Date:  1996-04       Impact factor: 4.666

10.  Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis.

Authors:  C Mohan; Y Shi; J D Laman; S K Datta
Journal:  J Immunol       Date:  1995-02-01       Impact factor: 5.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.